Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma. Of the patients who received the combination treatment, 96% responded. Patients did not experience dose-limiting toxicity.
The combination treatment has the potential to become a standard salvage chemotherapy regiment that will allow patients to still receive stem-cell transplants, says LaCasce. Twenty of the 48 evaluable patients went on to undergo an autologous stem cell transplant following the 2nd and third cycle.
The drug combination may significantly reduce the number of patients with relapsed or refractory Hodgkin lymphoma, says LaCasce.
Brentuximab also has future potential to be combined with a PD-1 Inhibitor.
<<< View more from the 2014 ASH Annual Meeting